Market Introduction
North America Point-of-Care Molecular Diagnostics Market Point-of-care molecular diagnostics include portable devices, and assays & kits used to detect and diagnose diseases in human samples, such as throat swab, blood, serum, and stool. Molecular diagnostics are shifting from centralized laboratories to decentralized point-of-care molecular testing. Due to its simplicity, convenience, rapid turnaround time, and potential to improve patient outcomes, POCT is rapidly gaining traction.Moreover, the growing demand for specific viral detection methods that consume less time for timely infection control is expected to bolster the market growth during the forecast period.
North America Point-of-Care Molecular Diagnostics Market The US has the highest number of COVID-19 cases of all countries in North America. This has negatively impacted various industries, and supply and distribution chains in the region. During the pandemic, life science companies shifted their focus in the development of novel drugs for the treatment of life-threatening diseases. In addition, the demand for rapid testing equipment has also increased, which is playing a prominent role in the growth of the North America point-of-care molecular diagnostics market.
📚 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲@ https://www.businessmarketinsights.com/sample/TIPRE00026192
Moreover, continuous spread of COVID-19 is bolstering the demand for point-of-care molecular diagnostic kits. North America Point-of-Care Molecular Diagnostics Market The adoption of these kits is boosting new product developments and launches. In March 2021, Eurofins’ Clinical Enterprise, Inc. obtained an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a direct-to-consumer (DTC) version of its EmpowerDX COVID-19 Home Collection Kit. Similarly, in July 2020, Clinical Diagnostics of Eurofins USA announced the availability of its pooled PCR test to detect SARS-CoV-2, which would substantially lower the cost per PCR test for clients.
Market Overview and Dynamics
North America Point-of-Care Molecular Diagnostics Market The North America Point-of-Care Molecular Diagnostics market is expected to reach US$ 2,110.1 million by 2028 from US$ 860.9 million in 2021. North America Point-of-Care Molecular Diagnostics Market The market is estimated to grow at a CAGR of 13.7% from 2021–2028. The ongoing COVID-19 pandemic has also created opportunities for the manufacturers of POC molecular diagnostic kits for the detection of the novel coronavirus. North America Point-of-Care Molecular Diagnostics Market For instance, ABBOTT, a global healthcare and medical equipment manufacturer, launched ID NOW. It is a molecular point-of-care instrument to detect new coronavirus infection in less than five minutes. ID NOW is a rapid, instrument-based, isothermal technique for detecting infectious illnesses qualitatively.
Its proprietary isothermal nucleic acid amplification product & services generates molecular data in seconds, allowing doctors to make evidence-based treatment decisions during a patient visit. North America Point-of-Care Molecular Diagnostics Market The ID NOW has not been certified or approved by the Food and Drug Administration (FDA). It has been approved by the FDA to use in authorized laboratories and patient care settings under an Emergency Use Authorization (EUA). Such innovations and product developments are expected to provide lucrative opportunities for the growth of the North America point-of-care molecular diagnostics market during the forecast period.
📚𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐋𝐢𝐧𝐤 @ https://www.businessmarketinsights.com/reports/north-america-point-of-care-molecular-diagnostics-market
𝐓𝐡𝐞 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
bioMérieux SA
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Enzo Biochem, Inc.
Abbott
binx health, Inc.
Meridian BioScience, Inc.
Biocartis
Quidel Corporation
Bio-Rad Laboratories, Inc.
Market Drivers
North America Point-of-Care Molecular Diagnostics Market Several key factors contribute to the expansion of the point-of-care molecular diagnostics market in North America. These factors include technological advancements, the growing demand for rapid diagnostics, the rising incidence of infectious diseases, increased healthcare spending, and regulatory support for new diagnostic technologies.
1. North America Point-of-Care Molecular Diagnostics Market Technological Advancements: The integration of advanced technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and isothermal amplification techniques into POC diagnostics has revolutionized the market. These technologies allow for faster, more accurate, and sensitive detection of a range of diseases, making them highly desirable for use in emergency situations or settings where quick diagnosis is critical.
2.Increasing Demand for Rapid Diagnostics: With the rise of pandemics such as COVID-19, there has been an increased demand for rapid diagnostics that can quickly identify infectious agents. POC molecular diagnostics enable near-instant results, which can reduce delays in treatment and improve patient outcomes.
3.Rising Incidence of Infectious Diseases: The growing prevalence of infectious diseases, including respiratory infections, sexually transmitted infections (STIs), and gastrointestinal diseases, has significantly driven the need for molecular diagnostics. The COVID-19 pandemic has heightened the awareness of the importance of timely detection and treatment, propelling the demand for point-of-care testing.
4.Healthcare Spending: Governments and healthcare systems across North America are increasingly investing in healthcare infrastructure and technology, including diagnostics. The push for cost-effective and efficient healthcare services has spurred the demand for POC molecular diagnostics, as they can be more affordable compared to traditional lab-based diagnostic tests when considering the broader healthcare system’s efficiency.
5.Regulatory Support: In North America, the Food and Drug Administration (FDA) and Health Canada have been actively supporting the approval and adoption of innovative molecular diagnostic technologies. North America Point-of-Care Molecular Diagnostics Market Regulatory bodies have streamlined approval processes for POC molecular diagnostic devices, which has encouraged greater innovation and the availability of new products.
The North American point-of-care (POC) molecular diagnostics market is expected to experience significant growth in the coming years. The market is projected to reach US$ 2,110.1 million by 2028, up from US$ 860.9 million in 2021, representing a compound annual growth rate (CAGR) of 13.7% from 2021 to 2028. This growth is largely driven by advances in molecular diagnostic technologies, the increasing demand for rapid testing, and the growing need for more accessible and efficient healthcare solutions, particularly in the wake of the COVID-19 pandemic.
The ongoing pandemic has greatly accelerated the adoption of point-of-care molecular diagnostics. The need for rapid and accurate detection of SARS-CoV-2 has led to the development of new diagnostic products that can be used outside traditional clinical settings. These advancements have not only enhanced diagnostic capabilities but also opened new avenues for manufacturers to explore and cater to the growing demand for molecular diagnostic kits.
Impact of COVID-19 on Market Dynamics
The COVID-19 pandemic has significantly influenced the North American POC molecular diagnostics market. With the virus spreading rapidly across the globe, the need for efficient and quick diagnostic solutions became critical in preventing further outbreaks and enabling timely treatment. Point-of-care molecular diagnostics offer the advantage of faster results, enabling healthcare providers to make quick, evidence-based treatment decisions.
One of the key innovations spurred by the pandemic is Abbott’s ID NOW system, a molecular point-of-care instrument designed to detect COVID-19 infection in under five minutes. ID NOW uses an isothermal nucleic acid amplification technique to provide qualitative results for infectious diseases in real-time. Although the ID NOW has not been fully approved by the FDA, it has received Emergency Use Authorization (EUA), enabling its use in authorized laboratories and patient care settings. This kind of innovation in rapid testing is expected to drive further growth in the POC molecular diagnostics market, with demand for similar solutions in the ongoing fight against COVID-19 and other infectious diseases.
Moreover, the increasing availability of COVID-19 diagnostic kits, including home collection kits and self-testing options, is further fueling market growth. For instance, Eurofins Clinical Enterprise received FDA authorization for its EmpowerDX COVID-19 Home Collection Kit in March 2021, which allows patients to collect samples in their homes and send them for testing. This shift toward consumer-directed molecular diagnostics is a key trend that is expected to persist post-pandemic as consumers seek more convenient and accessible healthcare solutions.
𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
You can see this-
Europe Electric Boat Market – https://www.openpr.com/news/3913133/europe-electric-boat-market-opportunities-challenges
Europe Stem Cell Therapy Market- https://www.openpr.com/news/3913146/europe-stem-cell-therapy-market-key-futuristic-trends
North America Medical Tubing Market- https://www.openpr.com/news/3913164/north-america-medical-tubing-market-global-analysis-with-focus
Europe Electric Ship Market – https://www.globalpostnews.com/uncategorized/europe-electric-ship-market-key-details-and-outlook-by-top-companies-till-2028/
